Zacks Research Issues Negative Outlook for TBPH Earnings

Theravance Biopharma, Inc. (NASDAQ:TBPH) – Zacks Research lowered their Q1 2026 earnings estimates for Theravance Biopharma in a research note issued on Wednesday, February 26th. Zacks Research analyst R. Department now anticipates that the biopharmaceutical company will post earnings per share of ($0.38) for the quarter, down from their prior forecast of ($0.21). The consensus estimate for Theravance Biopharma’s current full-year earnings is ($1.09) per share. Zacks Research also issued estimates for Theravance Biopharma’s Q2 2026 earnings at ($0.37) EPS and Q3 2026 earnings at ($0.07) EPS.

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $15.00 target price on shares of Theravance Biopharma in a report on Tuesday, February 25th. Four research analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. Based on data from MarketBeat.com, Theravance Biopharma currently has a consensus rating of “Hold” and an average price target of $13.75.

Theravance Biopharma Stock Down 0.5 %

Shares of NASDAQ:TBPH opened at $9.10 on Monday. The company has a market cap of $447.48 million, a P/E ratio of -9.01 and a beta of 0.21. Theravance Biopharma has a 52 week low of $7.44 and a 52 week high of $10.90. The company has a 50-day moving average price of $9.31 and a 200 day moving average price of $8.95.

Theravance Biopharma (NASDAQ:TBPH) last announced its quarterly earnings data on Wednesday, February 26th. The biopharmaceutical company reported ($0.31) EPS for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.26). The firm had revenue of $18.75 million during the quarter, compared to analyst estimates of $29.90 million. Theravance Biopharma had a negative net margin of 78.18% and a negative return on equity of 24.79%.

Insider Buying and Selling at Theravance Biopharma

In other news, SVP Rhonda Farnum sold 4,000 shares of the firm’s stock in a transaction that occurred on Tuesday, January 21st. The shares were sold at an average price of $9.00, for a total transaction of $36,000.00. Following the completion of the transaction, the senior vice president now directly owns 309,565 shares of the company’s stock, valued at $2,786,085. This trade represents a 1.28 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. 6.90% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the business. Aquatic Capital Management LLC purchased a new position in shares of Theravance Biopharma during the 4th quarter worth approximately $25,000. KLP Kapitalforvaltning AS purchased a new position in shares of Theravance Biopharma during the 4th quarter worth approximately $69,000. Quantbot Technologies LP purchased a new position in shares of Theravance Biopharma during the 3rd quarter worth approximately $60,000. Teacher Retirement System of Texas purchased a new position in shares of Theravance Biopharma during the 4th quarter worth approximately $103,000. Finally, ClearAlpha Technologies LP purchased a new position in shares of Theravance Biopharma during the 4th quarter worth approximately $109,000. 99.10% of the stock is owned by hedge funds and other institutional investors.

Theravance Biopharma Company Profile

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology.
In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.